Select Topic:
Browse by Series:

Considering Off-Label Use of Ibrutinib in MCL

Insights From: Bijal D. Shah, MD, H. Lee Moffitt Cancer Center & Research Institute; Lauren C. Pinter-Brown, MD, UCI Health; Eduardo Sotomayor, MD, GW Cancer Center
Published: Monday, Feb 04, 2019



Transcript:

Eduardo Sotomayor, MD:
I am using ibrutinib with rituximab in patients with mantle cell lymphoma with a low-proliferation index. It was based on data from Michael Wang from The University of Texas MD Anderson Cancer Center in which he shows that the addition of rituximab to ibrutinib increases our complete response rate, CR rate, but again, in this specific population with a low-proliferation index. I might need to revisit that. Again, we cannot extrapolate data from one disease to the other, but there is now clearly an indication that in chronic lymphocytic leukemia [CLL], the addition of rituximab doesn
Slider Left
Slider Right


Transcript:

Eduardo Sotomayor, MD:
I am using ibrutinib with rituximab in patients with mantle cell lymphoma with a low-proliferation index. It was based on data from Michael Wang from The University of Texas MD Anderson Cancer Center in which he shows that the addition of rituximab to ibrutinib increases our complete response rate, CR rate, but again, in this specific population with a low-proliferation index. I might need to revisit that. Again, we cannot extrapolate data from one disease to the other, but there is now clearly an indication that in chronic lymphocytic leukemia [CLL], the addition of rituximab doesn
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x